Your browser doesn't support javascript.
loading
Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients.
Hricik, Donald E; Formica, Richard N; Nickerson, Peter; Rush, David; Fairchild, Robert L; Poggio, Emilio D; Gibson, Ian W; Wiebe, Chris; Tinckam, Kathryn; Bunnapradist, Suphamai; Samaniego-Picota, Milagros; Brennan, Daniel C; Schröppel, Bernd; Gaber, Osama; Armstrong, Brian; Ikle, David; Diop, Helena; Bridges, Nancy D; Heeger, Peter S.
Afiliación
  • Hricik DE; Department of Medicine, University Hospitals Case Medical Center, Cleveland, Ohio;
  • Formica RN; Departments of Medicine and Surgery, Yale University School of Medicine, New Haven, Connecticut;
  • Nickerson P; College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada;
  • Rush D; College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada;
  • Fairchild RL; Department of Immunology and Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio;
  • Poggio ED; Department of Immunology and Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio;
  • Gibson IW; College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada;
  • Wiebe C; College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada;
  • Tinckam K; Department of Medicine, University of Toronto, Toronto, Ontario, Canada;
  • Bunnapradist S; Department of Medicine, University of California at Los Angeles Medical Center, Los Angeles, California;
  • Samaniego-Picota M; Department of Medicine, University of Michigan Medical Center, Ann Arbor, Michigan;
  • Brennan DC; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri;
  • Schröppel B; Department of Medicine and Recanati Miller Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, New York;
  • Gaber O; Department of Surgery, Houston Methodist Hospital, Houston, Texas; Weil Cornell Medical College, New York, New York;
  • Armstrong B; Rho, Chapel Hill, North Carolina; and.
  • Ikle D; Rho, Chapel Hill, North Carolina; and.
  • Diop H; Transplantation Branch, National Institute Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Bridges ND; Transplantation Branch, National Institute Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Heeger PS; Department of Medicine and Recanati Miller Transplant Institute, Icahn School of Medicine at Mount Sinai, New York, New York; peter.heeger@mssm.edu.
J Am Soc Nephrol ; 26(12): 3114-22, 2015 Dec.
Article en En | MEDLINE | ID: mdl-25925687
Concerns about adverse effects of calcineurin inhibitors (CNIs) have prompted development of protocols that minimize their use. Whereas previous CNI withdrawal trials in heterogeneous cohorts showed unacceptable rates of acute rejection (AR), we hypothesized that we could identify individuals capable of tolerating CNI withdrawal by targeting immunologically quiescent kidney transplant recipients. The Clinical Trials in Organ Transplantation-09 Trial was a randomized, prospective study of nonsensitized primary recipients of living donor kidney transplants. Subjects received rabbit antithymocyte globulin, tacrolimus, mycophenolate mofetil, and prednisone. Six months post-transplantation, subjects without de novo donor-specific antibodies (DSAs), AR, or inflammation at protocol biopsy were randomized to wean off or remain on tacrolimus. The intended primary end point was the change in interstitial fibrosis/tubular atrophy score between implantation and 24-month protocol biopsies. Serially collected urine CXCL9 ELISA results were correlated with outcomes. The study was terminated prematurely because of unacceptable rates of AR (4 of 14) and/or de novo DSAs (5 of 14) in the tacrolimus withdrawal arm. Positive urinary CXCL9 predated clinical detection of AR by a median of 15 days. Analyses showed that >16 HLA-DQ epitope mismatches and pretransplant, peripheral blood, donor-reactive IFN-γ ELISPOT assay results correlated with development of DSAs and/or AR on tacrolimus withdrawal. Although data indicate that urinary CXCL9 monitoring, epitope mismatches, and ELISPOT assays are potentially informative, complete CNI withdrawal must be strongly discouraged in kidney transplant recipients who are receiving standard-of-care immunosuppression, including those who are deemed to be immunologically quiescent on the basis of current clinical and laboratory criteria.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos HLA-DQ / Tacrolimus / Privación de Tratamiento / Inhibidores de la Calcineurina / Rechazo de Injerto / Riñón Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Soc Nephrol Asunto de la revista: NEFROLOGIA Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos HLA-DQ / Tacrolimus / Privación de Tratamiento / Inhibidores de la Calcineurina / Rechazo de Injerto / Riñón Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Soc Nephrol Asunto de la revista: NEFROLOGIA Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos